Endometriosis Epidemiology Forecast Report 2021-2030 - Focus on US, France, Germany, Italy, Spain, UK, and Japan - ResearchAndMarkets.com

The "Endometriosis - Epidemiology Forecast to 2030" report has been added to ResearchAndMarkets.com's offering.

This report provides an overview of the risk factors, comorbidities, and the global and historical epidemiological trends for endometriosis in the seven major markets (7MM: US, France, Germany, Italy, Spain, UK, and Japan).

The report includes a 10-year epidemiology forecast for the diagnosed prevalent cases of endometriosis. The diagnosed prevalent cases of endometriosis are segmented by age (12-54 years) and laparoscopy confirmation status (whether suspected or confirmed endometriosis).

The report also includes the diagnosed prevalent cases of endometriosis further segmented by ASRM stage and classified as Stage I (Minimal), Stage II (Mild), Stage III (Moderate), or Stage IV (Severe); phenotype: Superficial Peritoneal Endometriosis (SUP), Ovarian Endometrioma (OMA), and Deep Infiltrating Endometriosis (DIE); cases undergoing laparoscopy; and comorbidities such as chronic pelvic pain (CPP), dysmenorrhea, and dyspareunia.

The following data describes epidemiology of endometriosis. In the 7MM, The publisher epidemiologists forecast a decrease in the diagnosed prevalent cases of endometriosis from 3,317,609 cases in 2020 to 3,232,223 cases in 2030, at an AGR of -0.26% over the forecast period. Younger adult women are predominantly affected.

These findings are in line with the publisher estimates and these trends are reflected in the publisher's forecast for the diagnosed prevalent cases for the 7MM.

Scope

• The Endometriosis Epidemiology Report provides an overview of the risk factors and global trends of Endometriosis in the seven major markets (7MM: US, France, Germany, Italy, Spain, UK, and Japan).
• The report includes a 10-year epidemiology forecast for the diagnosed prevalent cases of endometriosis. The diagnosed prevalent cases of endometriosis are segmented by age (12-54 years) and laparoscopy confirmation status (whether suspected or confirmed endometriosis). The report also includes the diagnosed prevalent cases of endometriosis further segmented by ASRM stage and classified as Stage I (Minimal), Stage II (Mild), Stage III (Moderate), or Stage IV (Severe); phenotype: Superficial Peritoneal Endometriosis (SUP), Ovarian Endometrioma (OMA), and Deep Infiltrating Endometriosis (DIE); cases undergoing laparoscopy; and comorbidities such as chronic pelvic pain (CPP), dysmenorrhea, and dyspareunia.
• The endometriosis epidemiology report is written and developed by Masters- and PhD-level epidemiologists.
• The Epidemiology Report is in-depth, high quality, transparent and market-driven, providing expert analysis of disease trends in the 7MM.

Key Topics Covered:

1 Endometriosis: Executive Summary

1.1 Catalyst

1.2 Related Reports

1.3 Upcoming Reports

2 Epidemiology

2.1 Disease Background

2.2 Risk Factors and Comorbidities

2.3 Global and Historical Trends

2.4 7MM Forecast Methodology

2.4.1 Sources

2.4.2 Forecast Assumptions and Methods

2.4.3 Diagnosed Prevalent Cases of Endometriosis

2.4.4 Diagnosed Prevalent Cases of Endometriosis by Laparoscopy Confirmation Status

2.4.5 Diagnosed Prevalent Cases of Endometriosis by ASRM Stage

2.4.6 Diagnosed Prevalent Cases of Endometriosis by Phenotype

2.4.7 Diagnosed Prevalent Cases of Endometriosis Undergoing Laparoscopy

2.4.8 Diagnosed Prevalent Cases of Endometriosis with Comorbidities

2.5 Epidemiological Forecast for Endometriosis (2020-2030)

2.5.1 Diagnosed Prevalent Cases of Endometriosis

2.5.2 Age-Specific Diagnosed Prevalent Cases of Endometriosis

2.5.3 Diagnosed Prevalent Cases of Endometriosis by Laparoscopy Confirmation Status

2.5.4 Diagnosed Prevalent Cases of Endometriosis by Stage

2.5.5 Diagnosed Prevalent Cases of Endometriosis by Phenotype

2.5.6 Diagnosed Prevalent Cases of Endometriosis Undergoing Laparoscopy

2.5.7 Diagnosed Prevalent Cases of Endometriosis with Comorbidity

2.6 Discussion

2.6.1 Epidemiological Forecast Insight

2.6.2 COVID-19 Impact

2.6.3 Limitations of the Analysis

2.6.4 Strengths of the Analysis

3 Appendix

For more information about this report visit https://www.researchandmarkets.com/r/kouf7i

View source version on businesswire.com: https://www.businesswire.com/news/home/20220215005831/en/